GLP-1 medications significantly lower your appetite, but they certainly do not completely stop this natural and challenging Metabolic Adaptation process
Sharon Barr, executive vice president, biopharmaceuticals R&D at AstraZeneca, said, Building on the promising Phase I clinical data generated by Eccogene, we believe this oral GLP-1RA molecule could offer alternatives to current injectable therapies both as a potential monotherapy as well as in combination for cardiometabolic diseases such as type 2 diabetes, as well as for obesity
Type 2 Diabetes and Cancer: Umbrella Review of Meta-Analyses of Observational Studies
By helping the liver process and eliminate fat more efficiently, they support fat burning while boosting metabolism for longer-lasting results
Hasanah and Warnasih 2020
7.2 Comparing with the novel metabolic target drugs As the FXR-activating function of GLP-1RAs, FXR agonists may have the same effect as GLP-1RAs ( In reducing the risk of major adverse liver outcomes and HCC, large-scale observational studies and meta-analyses have demonstrated that GLP-1RA and SGLT2i exhibit comparable protective effects, with both showing significant superiority over traditional hypoglycemic agents such as DPP-4i and sulfonylureas
